Pfizer Inc. (PFE) News Headlines

▮ More

Date

Headline

2/11/2019 10:03:47 PM Merck KGaA And Pfizer : FDA Accepts For Priority Review SBLA For BAVENCIO

2/11/2019 5:23:03 PM Pfizer: XTANDI Plus Androgen Deprivation Therapy Meets Endpoint In ARCHES Trial

2/11/2019 5:11:28 PM Pfizer, Astellas: Phase 3 ARCHES Trial In Men With MHSPC Met Primary Endpoint

2/1/2019 9:25:00 AM Pfizer Gets Positive CHMP Opinion For Vizimpro 45 Mg

2/1/2019 9:17:50 AM Pfizer Receives Positive CHMP Opinion For Vizimpro 45 Mg

1/29/2019 7:18:18 AM Pfizer Q4 Results Beat View; But FY19 Outlook Disappoints

1/29/2019 6:50:47 AM Pfizer Inc. Q4 adjusted earnings Beat Estimates

1/29/2019 6:45:45 AM Pfizer Q4 Reported Loss Per Share $0.07; Adj EPS $0.64

1/29/2019 6:39:19 AM Pfizer, Lilly Announce Results From Phase 3 Study Of Tanezumab In OA Pain

1/29/2019 6:30:43 AM Pfizer And Eli Lilly Report Positive Top-line Results From Phase 3 Study Evaluating Tanezumab

1/29/2019 6:06:03 AM Pfizer Q4 18 Earnings Conference Call At 10:00 AM ET

1/15/2019 1:38:34 AM First Device For Congenital Heart Defect, AIMT & US Shutdown, ASLN On Watch

1/14/2019 8:07:35 AM Pfizer Says FDA Accepts Regulatory Submissions For Review Of Tafamidis

1/14/2019 8:01:49 AM Pfizer : FDA Accepts Regulatory Submissions For Review Of Tafamidis To Treat Transthyretin Amyloid Cardiomyopathy

1/7/2019 10:30:13 AM Pfizer To Present At The J.P. Morgan Conference; Webcast At 11:30 AM ET

1/7/2019 8:25:04 AM Pfizer To Use CytoReason's Machine Learning Model For Drug Discovery

1/7/2019 8:08:50 AM CytoReason Signs Deal With Pfizer To Utilize CytoReason’s Machine Learning Model Of Immune System For Drug Discovery

1/3/2019 8:33:35 AM Pfizer Begins Phase 2b/3 Clinical Trial For Oral JAK3 Inhibitor, PF-06651600

12/22/2018 2:51:35 PM Merck KGaA & Pfizer Decide To Discontinue JAVELIN Ovarian 100 Study Of Avelumab

12/21/2018 12:12:29 AM Pfizer Discontinues Phase 2b STRIVE Clinical Trial Due To Futility